Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$50.14 USD

50.14
466,690

-2.32 (-4.42%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 250)

Industry: Medical Info Systems

Zacks News

Surging Earnings Estimates Signal Upside for Omnicell (OMCL) Stock

Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

CLOV Q3 Estimates Unchanged Before Earnings: How to Play the Stock?

The continued strength in Clover Health's offerings is likely to have driven the company's performance in the third quarter.

OMCL Stock Soars on Q3 Earnings & Revenue Beat, '24 EPS View Raised

Omnicell continues its trend of impressive results in the third quarter of 2024.

Omnicell, Inc. (OMCL) Soars to 52-Week High, Time to Cash Out?

Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Omnicell (OMCL) Beats Q3 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 36.59% and 1.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell

Medical Systems, 10x Genomics and Omnicell have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Gain From Healthcare Digitization

Zacks Medical Info Systems industry stocks like Inspire Medical Systems, 10x Genomics and Omnicell are expected to gain from the GenAI wave.

Omnicell (OMCL) Moves to Strong Buy: Rationale Behind the Upgrade

Omnicell (OMCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Best Momentum Stocks to Buy for October 4th

OMCL and SFBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 4, 2024.

New Strong Buy Stocks for October 4th

KUBTY, OMCL, PDFS, RYAAY and HTH have been added to the Zacks Rank #1 (Strong Buy) List on October 4, 2024.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

Smart Beta ETF report for XHE

Should You Continue to Retain OMCL Stock in Your Portfolio Now?

Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.

Earnings Estimates Moving Higher for Omnicell (OMCL): Time to Buy?

Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Omnicell (OMCL) Introduces Central Med Automation Service

Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.

Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down

Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.

Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 218.75% and 9.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?

Hims & Hers Health (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?

Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omnicell (OMCL) Banks on Product Launches, Global Growth

Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.

Here's Why Omnicell (OMCL) Should be in Your Portfolio Now

A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).

Why Is Inspire (INSP) Down 7.3% Since Last Earnings Report?

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Omnicell (OMCL) Gains From New Offerings Amid Cost Woes

With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.

Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y

Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.

Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 137.50% and 4.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?